UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000035926
Receipt No. R000040217
Scientific Title An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)
Date of disclosure of the study information 2019/03/11
Last modified on 2019/05/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)
Acronym An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between DLB and AD
Scientific Title An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)
Scientific Title:Acronym An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between DLB and AD
Region
Japan

Condition
Condition dementia with Lewy bodies (DLB) , Alzheimer's disease (AD)
Classification by specialty
Neurology Psychiatry
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The objective of this research is to determine how accurately the electroencephalogram (EEG) analysis program can identify subjects with probable DLB among subjects including those with probable AD.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Accuracy of the EEG analysis program in identifying subjects with a diagnosis of probable DLB and subjects with a diagnosis of probable AD (on the basis of the clinical diagnostic criteria)
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Diagnosis
Type of intervention
Other
Interventions/Control_1 Standardized EEG recording will be acquired and analyzed with the EEG analysis program.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
50 years-old <=
Age-upper limit
90 years-old >=
Gender Male and Female
Key inclusion criteria 1)50-90 years of age, inclusive.
2)Patients with DLB, if applicable, who are identified as suffering from probable DLB according to the revised consensus criteria.Patients with AD, if applicable, who are identified as suffering from probable AD according to the NIAAA criteria, except for patients with probable AD who meet the criteria for possible DLB. To confirm this, the subject must have undergone sufficient clinical evaluation.
3)Mini Mental State Examination score between 14 to 26.
4)Results available from MRI or CT scan performed within 12 months prior to the screening visit to rule out possible vascular dementia.
5)Subject or responsible caregiver provides informed consent for the subject to participate in the research.
Key exclusion criteria 1)Subject or responsible caregiver is unable or unwilling to give informed consent.
2)Presence of local or diffuse vascular lesions on MRI or CT, where this is thought to be the cause of, or contribute to the severity of the subject's dementia.
3)Suffering from a significant neurologic disease other than probable DLB or AD.
4)Systemic diseases possibly contributing to the severity of dementia.
5)History of alcohol or drug abuse or dependence within the past 2 years.
6)History of schizophrenia.
7)Any significant systemic illness or unstable medical condition that may affect EEG.
8)Use of specific medications:
a)Centrally active beta-blockers (propranolol), methyldopa and clonidine within 4 weeks prior to screening, narcotics.
b)Use of anti-Parkinsonism medications other than levodopacarbidopa, or levodopa benserazide within 4 weeks prior to screening.
c)Neuroleptics or narcotic analgesics within 4 weeks prior to screening
d)Long acting benzodiazepines or barbiturates within 4 weeks prior to screening
e)Use of short-acting anxiolytics or sedative hypnotics more than 2 times per week within 4 weeks prior to screening.
9)Patients currently using memantine. Cholinesterase inhibitors are permitted if doses are stable for 4 weeks prior to screening.
10)Use of any investigational drugs within 30 days or 5 half lives prior to screening.
11)Subjects who, in the Principal Investigator's opinion, are unlikely to comply with the EEG recording procedure.
Target sample size 40

Research contact person
Name of lead principal investigator
1st name Etsuro
Middle name
Last name Mori
Organization Osaka University United Graduate School of Child Development
Division name Department of Behavioral Neurology and Neuropsychiatry
Zip code 565-0871
Address 2-2, Yamadaoka, Suita Osaka
TEL 06-6879-3373
Email dbnn@psy.med.osaka-u.ac.jp

Public contact
Name of contact person
1st name Etsuro
Middle name
Last name Mori
Organization Osaka University United Graduate School of Child Development
Division name Department of Behavioral Neurology and Neuropsychiatry
Zip code 565-0871
Address 2-2, Yamadaoka, Suita Osaka
TEL 06-6879-3373
Homepage URL
Email dbnn@psy.med.osaka-u.ac.jp

Sponsor
Institute Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development
Institute
Department

Funding Source
Organization Mentis Cura AS
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Osaka University Clinical Research Review Committee
Address 2-2, Yamadaoka, Suita Osaka
Tel 06-6210-8296
Email rinri@hp-crc.med.osaka-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 03 Month 11 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2019 Year 02 Month 13 Day
Date of IRB
2019 Year 03 Month 08 Day
Anticipated trial start date
2019 Year 04 Month 10 Day
Last follow-up date
2020 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 02 Month 19 Day
Last modified on
2019 Year 05 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040217

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.